Franklin Resources
RPRX icon

Franklin Resources’s Royalty Pharma RPRX Stock Holding History

Franklin Resources’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$113M Buy
2,007,750
+289,568
+17% +$15.1M 0.02% 433
2026
Q1 		$82.4M Buy
1,718,182
+1,040,698
+154% +$45.6M 0.02% 482
2025
Q4 		$26.2M Sell
677,484
-110,533
-14% -$4.22M 0.01% 868
2025
Q3 		$27.8M Sell
788,017
-146,205
-16% -$5.29M 0.01% 846
2025
Q2 		$33.7M Buy
934,222
+151,248
+19% +$5.01M 0.01% 755
2025
Q1 		$24.4M Buy
782,974
+243,493
+45% +$7.72M 0.01% 838
2024
Q4 		$13.8M Sell
539,481
-921,034
-63% -$24.4M ﹤0.01% 1019
2024
Q3 		$40.7M Buy
1,460,515
+70,130
+5% +$1.94M 0.01% 673
2024
Q2 		$36.7M Buy
1,390,385
+165,012
+13% +$4.57M 0.01% 651
2024
Q1 		$37.2M Buy
1,225,373
+1,129,012
+1,172% +$33.3M 0.01% 668
2023
Q4 		$2.71M Buy
96,361
+25,716
+36% +$707K ﹤0.01% 1300
2023
Q3 		$1.92M Buy
70,645
+16,657
+31% +$495K ﹤0.01% 1403
2023
Q2 		$1.66M Buy
53,988
+13,268
+33% +$449K ﹤0.01% 1475
2023
Q1 		$1.47M Sell
40,720
-1,085
-3% -$40.2K ﹤0.01% 1426
2022
Q4 		$1.65M Buy
41,805
+15,702
+60% +$655K ﹤0.01% 1418
2022
Q3 		$1.05M Sell
26,103
-107,946
-81% -$4.61M ﹤0.01% 1506
2022
Q2 		$5.63M Buy
134,049
+3,478
+3% +$143K ﹤0.01% 1082
2022
Q1 		$5.09M Buy
130,571
+791
+0.6% +$31.1K ﹤0.01% 1164
2021
Q4 		$5.17M Buy
129,780
+117,170
+929% +$4.55M ﹤0.01% 1213
2021
Q3 		$456K Sell
12,610
-401,943
-97% -$15.6M ﹤0.01% 1925
2021
Q2 		$17M Sell
414,553
-705,952
-63% -$30M 0.01% 901
2021
Q1 		$48.9M Buy
1,120,505
+2,301
+0.2% +$109K 0.02% 627
2020
Q4 		$56M Sell
1,118,204
-73,218
-6% -$3.11M 0.02% 558
2020
Q3 		$50.1M Sell
1,191,422
-8,578
-0.7% -$368K 0.02% 555
2020
Q2 		$51.7M Buy
+1,200,000
New +$59.4M 0.03% 521

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources's RPRX Position: Q2 2026 in Review

Franklin Resources increased its Royalty Pharma (RPRX) stake by 17% in Q2 2026, buying an estimated $15.1M and bringing the position to 2,007,750 shares worth $113M. The position accounts for 0.02% of the portfolio, ranked #433.

Franklin Resources first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Franklin Resources held 2,007,750 shares of Royalty Pharma worth $113M as of Q2 2026.
  • Franklin Resources bought 289,568 Royalty Pharma shares in Q2 2026, an estimated $15.1M.
  • Royalty Pharma made up 0.02% of Franklin Resources's portfolio in Q2 2026, its #433 holding.
  • Franklin Resources first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.